Monopar (MNPR) Insider Vesting: 4,327 Shares Settled, Tax Withholding $81.67
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) insider filing: Andrew Cittadine, the company's Chief Operating Officer and a director, reported equity activity dated 09/30/2025. He received 4,327 shares upon vesting and settlement of restricted stock units. To satisfy tax withholding on the vesting, 1,896 shares were surrendered at an indicated price of $81.67 per share.
After these transactions the filing shows beneficial ownership figures reported on the form: 50,185 shares following the acquisition line and 48,289 shares following the withholding line; the form also lists 38,674 restricted stock units/RSU-related shares held following the reported transactions. The form is executed by attorney-in-fact Quan Vu on 10/02/2025.
Positive
- 4,327 shares acquired on vesting and settlement of RSUs, reflecting compensation alignment
- No open-market sale reported beyond tax withholding, indicating no active divestiture
Negative
- 1,896 shares withheld to pay taxes at $81.67, reducing the reporting person’s net shares
Insights
Routine executive RSU vesting with tax withholding; no open-market sale reported.
The filing documents scheduled vesting of RSUs rather than an open-market purchase or sale. That indicates the change in the reporting person’s common stock position resulted from compensation plan mechanics, not a discretionary market trade. Because shares were withheld to cover taxes, there is no net sale disclosed beyond the withholding transaction documented at $81.67 per share.
Vesting schedule consistent with prior grants; partial settlement reduced outstanding RSUs.
The report references grant schedules from 2022, 2023, and 2025 and shows 4,327 RSUs vested and settled on 09/30/2025, with 1,896 shares withheld for tax. The filing also lists remaining RSU-related shares (38,674), which reflects ongoing vesting schedules extending through 2028 as disclosed in the explanations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 4,327 | $0.00 | -- |
| Exercise | Common Stock | 4,327 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,896 | $81.67 | $155K |
Footnotes (1)
- Represents shares acquired on vesting and settlement of restricted stock units. Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
